Single peptide Vial strength 10 mg
Survodutide10 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
Survodutide, explained simply
An investigational metabolic compound combining GLP-1 and glucagon receptor activity in weight and liver research.
Research area
Weight and metabolic liver disease
How it works
Survodutide is an investigational agonist of the GLP-1 and glucagon receptors.
Why it matters
Research places it among candidates for obesity and metabolic liver disease.
What has been observed
Phase 2 clinical studies measured changes in body weight against placebo.
Effects and points to consider
Complete results and regulatory assessments are needed to define appropriate use, safety, and formulations.
01 / Vial strength 10 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 10 mg Survodutide |
|---|---|
| Final volume | 2 mL |
| Concentration | 5 mg/mL |
| One U-100 unit | 50 mcg in 0.01 mL |
Standard / Gradual Titration (2 mL = 5 mg/mL)
| Week | Weekly Dose (mg) | Weekly Dose (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 600 mcg | 12 units (0.12 mL) |
| Weeks 3–4 | 1.2 mg | 1200 mcg | 24 units (0.24 mL) |
| Weeks 5–6 | 1.8 mg | 1800 mcg | 36 units (0.36 mL) |
| Weeks 7–8 | 2.4 mg | 2400 mcg | 48 units (0.48 mL) |
| Weeks 9–10 | 3.6 mg | 3600 mcg | 72 units (0.72 mL) |
| Weeks 11–12 | 4.8 mg | 4800 mcg | 96 units (0.96 mL) |
| Week 13+ | 6.0 mg | 6000 mcg | 120 units (1.20 mL)* |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.